These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
498 related articles for article (PubMed ID: 17404087)
1. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087 [TBL] [Abstract][Full Text] [Related]
2. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related]
3. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948 [TBL] [Abstract][Full Text] [Related]
4. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543 [TBL] [Abstract][Full Text] [Related]
5. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582 [TBL] [Abstract][Full Text] [Related]
6. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391 [TBL] [Abstract][Full Text] [Related]
7. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476 [TBL] [Abstract][Full Text] [Related]
8. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
10. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Newby JC; Johnston SR; Smith IE; Dowsett M Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855 [TBL] [Abstract][Full Text] [Related]
11. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012 [TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Shao YY; Kuo KT; Hu FC; Lu YS; Huang CS; Liau JY; Lee WC; Hsu C; Kuo WH; Chang KJ; Lin CH; Cheng AL Jpn J Clin Oncol; 2010 Apr; 40(4):286-93. PubMed ID: 20085902 [TBL] [Abstract][Full Text] [Related]
13. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679 [TBL] [Abstract][Full Text] [Related]
14. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979 [TBL] [Abstract][Full Text] [Related]
15. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399 [TBL] [Abstract][Full Text] [Related]
16. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539 [TBL] [Abstract][Full Text] [Related]
17. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249 [TBL] [Abstract][Full Text] [Related]
18. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W; J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570 [TBL] [Abstract][Full Text] [Related]
19. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Yamashita H; Nishio M; Ando Y; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H Endocr Relat Cancer; 2006 Sep; 13(3):885-93. PubMed ID: 16954437 [TBL] [Abstract][Full Text] [Related]
20. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience. Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]